Georgina V. Long, MD, PhD, on Resected Melanoma: Biomarkers for and Efficacy of Adjuvant Nivolumab vs Placebo
2023 ASCO Annual Meeting
Georgina V. Long, MD, PhD, of Melanoma Institute Australia and The University of Sydney, discusses new data showing that patients with resected stage IIB/C melanoma who were treated with adjuvant nivolumab had prolonged recurrence-free survival compared with placebo across all biomarker subgroups. The baseline biomarkers most predictive of prolonged recurrence-free survival with nivolumab were high interferon gamma score, high tumor mutational burden, CD8 T-cell infiltration, and low C-reactive protein (Abstract 9504).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Georgina V. Long:
Resected Stage 2B and 2C melanoma has a very poor prognosis. In fact, at five years, patients with stage 2C melanoma have a 45% risk of recurrence. And for stage 2B melanoma, 35% risk of recurrence. The survival of this group of patients is worse than that of stage 3A melanoma and the survival of stage 2C melanoma is equivalent to the survival of stage 3B melanoma. This is a poor prognostic group. Checkmate 76K explored adjuvant nivolumab versus placebo in resected stage 2B and 2C melanoma in patients who had undergone a wide local excision and a sentinel node biopsy, which was negative.
790 patients were randomized two to one to nivolumab versus placebo. We've already seen the relapse-free survival primary analysis last year, and there was a 58% reduction in the risk of recurrence with adjuvant nivolumab. We are now presenting the exploratory biomarker analysis from this trial. So baseline, primary melanoma tissue, and baseline CRP, serum CRP was correlated with outcome within each arm and versus each arm. And what we found was that for every biomarker subgroup, nivolumab improved the relapse-free survival over placebo.
And this included tumor mutation burden, interferon gamma, PD-L1 expression at baseline, CD8 infiltration at baseline, the CRP. So when we compared the prognostic biomarkers overall in the trial, we found that the two factors that were most important for prognosis, so predicting recurrence in the total trial population, that was the CRP and the stage. However, when we did our multivariate model to look at what was predictive of best outcome with adjuvant nivolumab over placebo, we found that the baseline biomarkers that were predictive or most predictive were the interferon gamma at baseline and the tumor mutation burden.
Our next steps are to make a multifactorial model, which includes both clinical and tissue biomarkers to predict outcome of patients with resected 2B and 2C melanoma treated with adjuvant nivolumab.
The ASCO Post Staff
James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital and National Taiwan University Cancer Center, discusses the latest data from the phase III KEYNOTE-789 study, which evaluated the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab in the treatment of adults with EGFR tyrosine kinase inhibitor–resistant, EGFR–mutated, metastatic nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA9000).
The ASCO Post Staff
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss the use of tumor treating fields therapy, in which electric fields disrupt processes critical for cancer cell viability. Already approved by the FDA to treat glioblastoma and mesothelioma, the treatment has extended overall survival in this phase III study of patients with metastatic non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, without exacerbating systemic toxicities (Abstract LBA9005).
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate cancer–specific, metastasis-free, and overall survival in patients receiving radiotherapy plus androgen-deprivation therapy for localized prostate cancer. These findings may help identify patients for therapy de-escalation trials (Abstract 5002).
The ASCO Post Staff
Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).
The ASCO Post Staff
Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.